SCHEMBL23149185

SCHEMBL23149185

O=C(COc1ccc(Cl)cn1)NC12CC(NCCOc3ccc(Cl)cc3)(C1)C2

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATF4 P18848 12/20 0.62
▸ RAB9A P51151 3/20 0.48
▸ NPC1 O15118 2/20 0.48
▸ TSHR P16473 1/20 0.48
▸ LMNA P02545 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ CASP3 P42574 1/20 0.41
▸ NFKB2 Q00653 1/20 0.41
▸ RELA Q04206 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ SENP8 Q96LD8 1/20 0.41
▸ SENP7 Q9BQF6 1/20 0.41
▸ SENP6 Q9GZR1 1/20 0.41
▸ KCNH2 Q12809 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ NR4A1 P22736 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23149156 0.90 ATF4 (0.78) ATF4RAB9ANPC1TSHRNPSR1
SCHEMBL19569415 0.89 ATF4 (0.80) ATF4RAB9ANPC1TSHRNPSR1
SCHEMBL23383990 0.79 ATF4 (0.80) ATF4RAB9ANPC1TSHRNPSR1
SCHEMBL21618335 0.79 ATF4 (0.56) ATF4RAB9ANPC1TSHRLMNA
SCHEMBL20974142 0.79 ATF4 (1.00) ATF4RAB9ANPC1TSHRALDH1A1
SCHEMBL20973815 0.78 ATF4 (0.64) ATF4
SCHEMBL30026071 0.78 ATF4 (0.64) ATF4
SCHEMBL20610464 0.77 ATF4 (0.67) ATF4RAB9ANPC1TSHRALDH1A1
SCHEMBL20610405 0.77 ATF4 (0.63) ATF4RAB9ANPC1TSHRKCNH2
SCHEMBL23149130 0.77 ATF4 (0.74) ATF4RAB9ANPC1TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210093619-A1 Chemical Compounds as ATF-4 Pathway Inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-04-01 — — US disclosed
US-20210093619-A1 Chemical Compounds as ATF-4 Pathway Inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-04-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210093619-A1 Chemical Compounds as ATF-4 Pathway Inhibitors ATF4, ATF1, XBP1 ATF4 1/4885RAB9A 3165/4885NPC1 514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback